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Abstract 
Background: Human papillomavirus positive (HPV+) head and neck squamous cell 
carcinoma (HNSCC) is an emerging disease, representing a distinct clinical and 
epidemiological entity. Understanding the genetic basis of this specific subtype of cancer 
could allow therapeutic targeting of affected pathways for a stratified medicine approach.  
Methods: Twenty HPV+ and 20 HPV- laser-capture microdissected oropharyngeal 
carcinomas were used for paired-end sequencing of hybrid-captured DNA, targeting 3,230 
exons in 182 genes often mutated in cancer. Copy number alteration (CNA) profiling, 
Sequenom MassArray sequencing and immunohistochemistry were used to further 
validate findings.  
Results: HPV+ and HPV- oropharyngeal carcinomas cluster into two distinct subgroups. 
TP53 mutations are detected in 100% of HPV negative cases and abrogation of the G1/S 
checkpoint by CDKN2A/B deletion and/or CCND1 amplification occurs in the majority of 
HPV- tumors.  
Conclusion: These findings strongly support a causal role for HPV, acting via p53 and RB 
pathway inhibition, in the pathogenesis of a subset of oropharyngeal cancers and suggest 
that studies of CDK inhibitors in HPV negative disease may be warranted. Mutation and 
copy number alteration of PI3 kinase (PI3K) pathway components appears particularly 
prevalent in HPV+ tumors and assessment of these alterations may aid in the 
interpretation of current clinical trials of PI3K, AKT and mTOR inhibitors in HNSCC.  
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Background 
 Human papillomavirus–related (HPV+) head and neck squamous cell carcinoma 
(HNSCC) is a subgroup of HNSCC where the incidence is increasing in most developed 
countries [1]. The vast majority of HPV+ HNSCC originate from the oropharynx, and in 
particular the tonsillar beds [2]. These tumors are almost exclusively associated with HPV-
16, have integrated and functionally active E6 and E7 viral oncoproteins, and compared to 
HPV-negative tumors appear to have an overall better outcome, independent of treatment 
modality [3].  
Whole-exome sequence analysis was previously performed to reveal the mutational 
landscape of HNSCC [4, 5]. These studies showed that over 80% of tumors contain TP53 
mutations and strikingly up to 20% have loss-of-function NOTCH1 mutations. However, in 
these two studies, only seven and four HPV+ samples were included respectively. Both 
studies confirmed the lack of TP53 mutations compared to HPV- samples, and overall, a 
lower mutational burden in HPV+ disease. 
To further understand the contribution of somatic genomic alteration in the pathogenesis 
of HPV+ HNSCC we employed paired-end sequencing of hybrid-captured DNA, targeting 
3,230 exons in 182 of the most common cancer-altered genes, plus 37 introns from 14 
genes often rearranged in cancer. 
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Methods 
Sample Collection, p16 staining and DNA Extraction.   
 Ethical approval for this study was granted by the UCL/UCLH Ethics Committee 
(Reference number 04/Q0505/59) with informed consent obtained where required. Based 
on the results of a power analysis and taking into account gender and age-matching 
requirements we selected twenty HPV+ and 20 HPV- oropharyngeal carcinomas (from 22 
HPV+ and 34 HPV- oropharyngeal cancer samples available to us), all formalin fixed 
paraffin-embedded (Table 1). Our power analysis suggested that by choosing the 
described number of samples there was just a under 90% chance of detecting moderate 
differences in the proportion of mutations between HPV+ and HPV- HNSCC samples (w = 
0.5, P = 0.05). 
Details of sample preparation and selection are illustrated in Figure 1. We confirmed HPV 
status by p16 staining, and by quantitative PCR for HPV-16 E6, having been shown to 
have 97% sensitivity, 94% specificity and to be the best discriminator of favourable 
outcome [6]. Sequencing of HPV DNA demonstrated 100% concordance of HPV status.  
All samples were laser-capture microdissected (LCM) to separate tumor epithelial from 
surrounding stromal tissues, enriching tumor DNA for further analyses. These were 
processed as 10 µm thick unstained slides which were reviewed by an expert pathologist 
who had marked the slides for tumor subtype enrichment in a corresponding H&E stained 
section. LCM was carried out on P.A.L.M. MembraneSlide 1.0 PEN slides (Zeiss 
Microimaging, Munich, Germany) using the Zeiss Palm MicrobeamTM system. Tissue was 
collected into extraction tubes and processed using the QIAamp DNA FFPE Tissue Kit 
(Qiagen, Hilden, Germany). Extracted DNA was quantified using a standardized 
PicoGreen fluorescence assay (LifeTechnologies, Carlsbad, CA).  
DNA Library Construction and Hybrid Capture.   
 At least 50ng and up to 200ng of extracted DNA was sheared to ~100-400 bp by 
sonication, followed by end-repair, dA-addition and ligation of indexed, Illumina 
sequencing adaptors. Sequencing libraries were hybridization captured using RNA-based 
baits (Agilent), targeting a total of 3,320 exons of 182 cancer-related genes (most 
commonly altered in cancer, from http://www.sanger.ac.uk/genetics/CGP/cosmic/) plus 37 
introns from 14 genes often rearranged in cancer (Additional File 1, Table S1). 
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Sequencing and primary sequence data analysis 
 Paired end sequencing (49 x 49 cycles) was performed using the HiSeq2000 
(Illumina). 6 samples yielded insufficient numbers of reads and were excluded from 
analysis. The summary of sequencing details is illustrated in Additional File 1, Table S2. 
Sequence data from gDNA, available from 18 HPV+ and 16 HPV- samples, were mapped 
to the reference human genome (hg19) using the BWA aligner [7]. PCR duplicate read 
removal and sequence metric collection was performed using Picard 
(http://picard.sourceforge.net) and SAMtools [8].  Local alignment optimization was 
performed using GATK [9]. Hybrid capture reagents included baits designed to capture 
unique regions of select viral genomes including HPV-16. Sequence read pairs were 
aligned to the reference genome of the respective viral genomes, and the number of pairs 
mapping to each viral genome was counted. A total HPV-16 aligned read count of >= 5 
reads per million was considered a positive HPV status, and <= 2 negative HPV status. 
Genomic alteration detection 
 Base substitution detection was performed using a Bayesian methodology, which 
allows detection of novel somatic mutations at low MAF and increased sensitivity for 
mutations at hotspot sites [10] through the incorporation of tissue-specific prior 
expectations: 			|			""  					"F"  0| ∝ 1  
|  0  0, where | is evaluated with a multinomial distribution of the 
observed allele counts using empirically observed error rates and   0 is the prior 
expectation of mutation in the tumor type. To detect indels, de-novo local assembly in 
each targeted exon was performed using the de-Bruijn approach [11]. Candidate calls are 
filtered using a series of quality metrics, including strand bias, read location bias and a 
custom database of sequencing artifacts derived from normal controls. Germline 
alterations are identified and filtered using dbSNP (version 135, 
http://www.ncbi.nlm.nih.gov/projects/SNP/) and subsequently annotated for known and 
likely somatic mutations using the COSMIC database (version 62, 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). Detection of copy-number 
alterations (CNAs) was performed by obtaining a log-ratio profile of the sample by 
normalizing the sequence coverage obtained at all exons against a process-matched 
normal control. The profile is segmented and interpreted using allele frequencies of ~1,800 
additional genome-wide SNPs to estimate tumor purity and copy number based on 
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established methods [12-14] by fitting parameters of the equation 
!"#$~&log*
+∗-./0123+∗*
+∗45678	+97:;<123+∗*
, where !"#$, >"#$ and p are the log-ratios and copy 
numbers at each segment and sample purity respectively. Focal amplifications are called 
at segments with ≥6 copies and homozygous deletions at 0 copies, in samples with purity 
>20%. 
A summary of known and likely somatic or functional base substitution and indel (short-
variant) alterations and of base substitution and indel (short-variant) alterations of 
unknown status detected by deep sequencing is illustrated in Additional File 1, Table S3 
and Additional File 1, Table S4, respectively. A summary of copy number alterations 
detected by deep sequencing is illustrated in Additional File 1, Table S5.  
 
Validation of selected mutations by Sequenom OncoCarta 
 DNA extracted from FFPE samples were sent to Sequenom (Hamburg, Germany) 
for blind testing and analysis, using Sequenom OncoCarta panels v1.0 and v3.0, as 
previously described [15]. 
Confirmation of copy number changes by Infinium CNA Profiling. 
 Using previously obtained Infinium HumanMethylation450 BeadChip methylation 
data on sequenced samples [16], the Bioconductor package ‘DNAcopy’ 
(http://bioc.ism.ac.jp/2.10/bioc/html/DNAcopy.html) [17] was applied to calculate the copy 
number of the majority of sequenced samples, as described previously [18]. All normalised 
and raw 450k methylation data were submitted to GEO (Gene Expression Omnibus, 
NCBI) according to instructions provided (GEO accession number: GSE38266). 
 
 
 
 
Immunohistochemistry and interpretation of results.   
 The sequenced 18 HPV+ and 16 HPV- HNSCC samples were stained for PTEN 
and for Cyclin D1. Staining for these particular targets was chosen as these were already 
implicated in HNSCC carcinogenesis and validated scoring systems are available [19, 20]. 
Antibody 04-409 (Millipore-Merck KGaA, Darmstadt, Germany) was used for PTEN 
staining and antibody P2D11F11 (Novocastra) was used Cyclin D1 staining of 10µm thick 
slides. The stained slides were examined and scored as previously described [19, 20], by 
two experienced histopathologists.  
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Statistical data analysis. 
 Significance of enrichment of observed genomic alterations in HPV+ and HPV- 
HNSCC cases was tested using the Pearson's chi-squared test. Relation of gender, tumor 
site, tumor grade, size of primary tumors (T), lymph node metastasis (N), smoking status 
and alcohol intake to the two tested groups was determined using the Wilcoxon rank sum 
test. Relation of age to the two groups was tested by a logistic regression model. The 
obtained p-values were corrected for multiple testing (FDR adjustment). Correlation of 
sequencing results with CCND1 and PTEN immunochemistry was tested using the 
Fisher’s Exact Test. 
 
Results 
Patient demographic data. 
 The median age is slightly higher in the HPV- group (58 vs. 56.5 years) (Table 1). 
Male to female ratio is similar between the Groups, and the majority of cases show 
moderately or poorly differentiated histology with evidence of lymph nodal involvement at 
presentation. In our cohort, as predicted, the vast majority of HPV- cases are in active 
smokers and/or heavy alcohol users (Table 1 and Figure 2). No significant relationship of 
gender, tumor site, tumor grade, size of primary tumors (T), lymph node metastasis (N), 
smoking status, determined using the Wilcoxon rank sum test, to any of the two tested 
groups (HPV+ HNSCC vs. HPV- HNSCC) was seen. Patients with high alcohol intake 
were significantly enriched in the HPV- group (Wilcoxon rank sum test; adjusted P-value < 
0.05).  
 
 
 
 
Next generation sequencing.  
 Sequence analysis revealed that HPV+ and HPV- oropharyngeal carcinomas 
cluster into two distinct subgroups, with few overlapping genetic alterations (Figures 2 and 
3). TP53 mutations are detected in 100% of HPV- samples (Figure 2; significant 
enrichment in HPV- group; chi-square test, q < 0.01). The list of observed TP53 mutations 
is illustrated in Additional File 1, Table S6. CCND1 amplifications (chi-square test, q < 
0.01) and CDKN2A/B deletions (chi-square test, q < 0.05) were exclusively detected in 
HPV- cases (in around 55% and 40% of cases). PIK3CA mutation or amplification, and 
PTEN inactivation by gene copy loss or mutation were seen in over 55% of HPV+ tumors, 
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and in 31% HPV- tumors. FBXW7 alterations were present in over 15% of all samples and 
SOX2 amplification in 12% of cases.  
 
Validation of obtained results.  
 For validation of our results, we applied Infinium CNA profiling, Sequenom 
OncoCarta panels v1.0 and v3.0 and immunohistochemistry. Copy number gains and 
losses detected by next generation sequencing (NGS) were interrogated by Infinium CNA 
profiling (Additional File 2, Figure S1).  48 of 50 (96%) copy number alterations detected 
by sequencing were confirmed (Figure 4). Furthermore, the detected mutations by NGS 
were validated by Sequenom OncoCarta panels v1.0 and v3.0 (Additional File 2, Figure 
S2). As our NGS technique targeted the whole gene sequence, whereas Sequenom 
OncoCarta panels only target specific mutational hotspots of certain genes, the majority of 
NGS detected mutations were not included in the Sequenom analysis.  Eight out of nine 
mutations that were detected by NGS were also confirmed by Sequenom. One PIK3CA 
mutation in sample P72_pos was called at 1% allele frequency by NGS, and this mutation 
was therefore unlikely to be detected by Sequenom analysis.   
 
For CCND1 and PTEN we also validated findings by immunohistochemistry in sample 
material from the 18 HPV+ and 16 HPV- HNSCC samples tested by NGS. Genomic 
alterations in CCND1 were confirmed by Cyclin D1 immunochemistry with strong 
expression of Cyclin D1 protein in 8 of 9 CCND1 amplified cases (and intermediate 
expression in the remaining case). Using all tested samples, significant correlation of 
CCND1 sequencing results with Cyclin D1 immunochemistry was observed (P = 7.34e-05; 
Fisher’s Exact Test). Representative samples are shown in Figure 5. PTEN loss and 
mutation were validated by immunohistochemistry (Figure 6). PTEN staining was negative 
in all cases in which NGS revealed a homozygous deletion or mutation. Four additional 
samples displayed low PTEN protein expression. In three of these cases a heterozygous 
deletion/single copy loss of PTEN was present, as detected by NGS. In the remaining 
sample other mechanisms may explain the loss of expression, such as an epigenetic 
alteration or changes in the post-transcriptional regulation of PTEN. Overall highly 
significant correlation of PTEN sequencing results with PTEN immunochemistry was 
demonstrated (P = 0.0009; Fisher’s Exact Test). 
Mutations reported in this study as “known somatic” were limited to those that have been 
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previously confirmed to be somatic in other tumors, through sequencing of matched 
normal specimens.  Consequently, we are confident that these alterations are somatic. 
 
Discussion 
 Overall, sequence analysis revealed that HPV+ and HPV- oropharyngeal 
carcinomas cluster into two distinct subgroups, with few overlapping genetic alterations. 
These data concur with epidemiological and clinical data, indicating that HPV+ HNSCC is 
a distinct disease entity [21, 22]. 
Our detection of TP53 mutations in 100% of HPV- samples, higher than previously 
reported [23], suggests that our approach of laser capture microdissection coupled with 
targeted deep sequencing is a highly sensitive method by which to assay specific tumor 
mutations. Taken together with the fact that in the HPV+ tumors, p53 function is 
suppressed by E6, our data suggest an obligate requirement for p53 abrogation in 
oropharyngeal tumorigenesis. One caveat in our study is that all HPV- samples analyzed 
were also p16 negative, thus it remains possible that in HPV- samples with elevated p16 
expression (e.g. through RB1 mutation), the frequency of TP53 mutation is less than 
100%.  
We identified only one TP53 mutation in an HPV+ tumor. However, this mutation (R290C, 
Additional File 1, Table S2) causes only a 40% decrease in TP53 function and has been 
detected in sarcomas harboring MDM2 amplification [24, 25]. 
Our data for HPV- oropharyngeal cancer indicate that the frequency of CCND1 
amplification (in around 55% of cases) and CDKN2A/B deletions (in around 55% of cases) 
are higher than previously reported [26]. CCND1 amplification has also been described in 
12% of non-small cell lung cancers [27] and in up to 41% of esophageal squamous cell 
carcinomas [28], suggesting that this could be one of the more common genetic 
alterations linked to smoking-induced epithelial malignancy. In HPV+ cancer, the 
oncoprotein E7 leads to cell cycle dysregulation by substituting for cyclin D gain-of-
function and cyclin dependent kinase inhibitor loss-of-function activities. Overall, this 
indicates that direct dysregulation of the cell cycle is a key mechanism for oropharyngeal 
tumors to evolve. 
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HPV+ HNSCC samples frequently harbor mutations or CNAs in genes implicated in 
activation of the PI3K/AKT/mTOR pathway. In particular, PIK3CA mutation and PTEN 
inactivation by gene copy loss or mutation were seen in over 60% of HPV+ tumors, and in 
31% HPV- tumors.  There is a significant relation between PIK3CA and PTEN, and HPV 
status; chi-square test, P < 0.001.  These findings may help to explain the high frequency 
of PI3K pathway activation in HPV+ HNSCC samples and the efficacy of mTOR inhibitors 
in xenograft studies with HPV+ cell lines previously reported [29]. It will be important to 
audit both the sequence and copy number of the PIK3CA and PTEN genes if such agents 
are tested in clinical trials for HPV-associated HNSCC.  
 
Our results suggest that mutations in FBXW7 may be enriched in HPV+ disease. FBXW7 
is an E3 ubiquitin ligase that targets a number of growth-promoting proteins for 
proteasomal degradation, including Cyclin E, MYC, NOTCH and mTOR [30, 31]. Loss of 
FBXW7 occurs in combination with NOTCH gain-of-function mutations in T-ALL [32], 
suggesting it may be an important target for FBXW7 ligase activity in these tumors. In 
contrast, HNSCC frequently display NOTCH loss-of-function-mutations [33, 34], thus in 
HNSCC, other substrates such as Cyclin E, MYC or mTOR may be the relevant targets for 
FBXW7. We found one HPV- sample harboring a NOTCH1 mutation, concurring with 
previous studies reporting NOTCH1 mutations in HNSCC [4, 5]. 
 
Two of our tested HPV+ samples harbored KRAS mutations. KRAS mutations have been 
associated with a history of smoking [35]. One of the patients was a smoker and in the 
other one the smoking status was unknown. HRAS mutations were not detected in any of 
our tested samples. In previous studies, mutations in the HRAS gene were mainly 
detected in oral cavity cancer samples [4, 5]. 
 
The SOX2 and PIK3CA genes both reside on the long arm of chromosome 3 (3q26) and 
these genes were amplified in three HPV+ samples and one HPV- tumor. While PIK3CA 
amplifications have previously been reported in HPV+ HNSCC [36, 37], SOX2 has 
recently been proposed as the critical target of 3q gains observed at a high frequency in 
squamous lung cancer [38] and in esophageal squamous cell carcinoma [39]. SOX2 is 
also frequently amplified and overexpressed in oral squamous cell carcinoma [40].  
Furthermore, SOX2 expression is upregulated in a subpopulation of putative HNSCC stem 
cells that displays characteristics of epithelial to mesenchymal transition (EMT), 
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associated with increased propensity for metastasis [41].  
We also demonstrate for the first time inactivating mutations in STK11 in HPV+ HNSCC. 
Loss of STK11 is associated with metastasis in head and neck cancer [42].  Furthermore, 
loss of function mutations in STK11 (LKB1) result in activation of mTORC1 signaling and 
can sensitize cells to mTOR inhibition [43, 44]. Mutations in these genes therefore (in 
addition to PIK3CA and PTEN) warrant evaluation as potential determinants of sensitivity 
to mTOR inhibitors currently in clinical trials for HNSCC [45]. 
Beyond the genes directly involved in signaling and cell cycle, we found amplifications in 
genes implicated in preventing apoptosis: BCL2L1 (6% amplification) and MCL1 (3% 
amplification), suggesting that direct suppression of apoptosis may also contribute to 
HNSCC pathogenesis.   
Receptor tyrosine kinase mutations, FGFR1, FGFR3 and EGFR, were only observed in 
HPV- tumors at low frequency.  
Overall, our data strongly support a causal role for HPV in oropharyngeal carcinogenesis 
by overcoming the requirement for genetic lesions in the TP53 and RB1 tumor suppressor 
pathways evident in the HPV- tumors. Our detection of frequent PI3K/AKT/mTOR pathway 
alterations in HPV+ tumors is consistent with a recent report demonstrating PI3K pathway 
activation and sensitivity to mTOR inhibition in both cervical carcinoma and HPV+ HNSCC 
[29]. Together, these studies provide a rationale for the testing of PI3K pathway inhibitors 
in HPV+ HNSCC. In HPV- tumors, the frequent alteration of CDKN2A/B and/or CCND1 
suggests that, if supported by functional data, trials with CDK inhibitors may be indicated. 
Our data support the observations by gene expression microarrays and by genome-wide 
methylation studies that HPV+ HNSCC is a distinct entity, with a distinct set of somatic 
alterations. However, it would appear that a core set of pathways (TP53, RB1/cell cycle 
and PI3K/AKT/mTOR) is compromised in both HPV+ and HPV- oropharyngeal tumors, 
thus targeted therapies directed against one or more of these pathways could be 
efficacious in both contexts.  
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CNA: Copy number alteration; EMT: epithelial to mesenchymal transition; FF: fresh-
frozen; FFPE: formalin-fixed paraffin-embedded; GEO: Gene Expression 
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Table 1: 
 
HPV+ (n=20) HPV- (n=20) 
Median Age (range) 56.5 years (42-81) 58 years (45-77) 
Gender 
M: 14 M: 14 
F: 6 F: 6 
Tumor site Oropharynx: 20 Oropharynx: 20 
Tumor grade 
Well diff: 1 Well diff: 0 
Mod diff: 9 Mod diff: 16 
Poorly diff: 10 Poorly diff: 4 
Tumor stage (T) 
T1: 5 T1: 1 
T2: 8 T2: 4 
T3: 3 T3: 5 
T4: 3 T4: 10 
N/a: 1 N/a: 0 
Cervical lymph node 
involvement (N) 
Yes: 16 Yes:13 
No: 2 No: 6 
N/a: 2 N/a: 1 
Smoking 
Ever: 9 Ever: 15 
Never: 8 Never: 0 
N/a: 3 N/a: 5 
Alcohol 
Heavy drinker (>20U/w): 2  Heavy drinker (>20U/w): 12  
Occ. alcohol: 5 Occ. alcohol: 3 
Never: 4 Never: 0 
N/a: 9 N/a: 5 
 
Table Legend. 
Table 1: Patient characteristics of selected HPV+ and HPV- HNSCC samples. 
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Figure Legends. 
Figure 1: Workflow of FFPE sample preparation and selection. 82 FFPE blocks [16]  
were stained for p16 of which 8 samples were excluded from further analysis, showing 
mixed p16 staining. 8 samples were excluded after the LCM step, yielding insufficient 
amounts or quality of DNA and 2 further samples were excluded due to inconsistent or 
borderline results in repeat E6 qPCR measurements. In total, 22 confirmed HPV+ (p16+ 
and E6 qPCR+) and 34 HPV- (p16- and E6 qPCR-) samples were suitable for further 
analysis. Following age and gender matching, twenty HPV+ HNSCC samples (red) and 20 
HPV- HNSCC samples (grey) were then selected for the final analysis (next-generation 
[NG] sequencing).  
 
Figure 2: Illustration of somatic events in HPV+ and HPV- HNSCC revealed by NGS 
of cancer related genes. Relevant demographic and histological data are described 
above the heatmap of genomic changes. The color coding of the observed changes and 
patient characteristics are explained in the key on the right. 
Figure 3: Hierarchical clustering of HPV+ and HPV- HNSCC samples using all 
detected genetic changes. HPV+ and HPV- HNSCC samples clustered in 100% of 
cases.  
 
Figure 4: Validation of copy number changes by Infinium CNA Profiling across all 
samples. A) 48 of 50 (96%) copy number alterations detected by sequencing were 
confirmed (green: confirmed, pink: not confirmed, grey: no data); B) Genetic changes in 
‘P17_neg’ detected by NGS (extracted from Figure 2); C) Illustration of copy number 
changes (obtained from Infinium CNA Profiling) in ‘P17_neg’. Both the loss of the 
CDKN2A and CDKN2B genes (in a region of loss within chromosome 9) and the gain of 
the CCND1 gene (in an amplified region of chromosome 11) are shown. Y-axis: log fold 
change of copy number, X-axis: copy number changes across all chromosomes. 
 
Figure 5: Validation of detected copy number alterations of Cyclin D1 (CCND1) by 
immunohistochemistry.  
Staining of HNSCC samples for Cyclin D1 confirmed strong expression in 8 of 9 CCND1 
amplified cases (and intermediate expression in the remaining case) compared with 
samples harboring no copy number alteration; Representative samples shown: Low levels 
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of CCND1 expression in the tumor tissue of sample ‘P38_pos’ (A) and sample ‘P29_neg’ 
(B); NGS: No CNA; High levels of Cyclin D1 expression in the tumor tissue of sample 
‘P12_neg’ (C) and sample ‘P17_neg’ (D); NGS: CCND1 copy number gain. 
 
Figure 6: Validation of detected PTEN copy number loss by immunohistochemistry.  
Staining of HNSCC samples for PTEN was negative in all cases in which deep 
sequencing revealed a homozygous deletion or mutation.  
Representative samples shown: Abundant PTEN expression in the tumor tissue of sample 
‘P26_pos’ (A) and sample ‘P70_neg’ (B); Deep-sequencing: No CNA; Absence of PTEN 
protein in the tumor tissue of sample ‘P60_pos’ (C) and sample ‘P13_pos’ (D); Deep-
sequencing: PTEN copy number loss. 
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